SCHEMBL2117129

SCHEMBL2117129

Cc1ccc(S(=O)(=O)Nc2cc(-c3cnco3)ccc2C)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.47
PKM P14618 1/20 0.47
POLB P06746 2/20 0.45
RAB9A P51151 1/20 0.45
SLC40A1 Q9NP59 1/20 0.45
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
PSEN1 P49768 1/20 0.42
PSEN2 P49810 1/20 0.42
APH1B Q8WW43 1/20 0.42
NCSTN Q92542 1/20 0.42
APH1A Q96BI3 1/20 0.42
PSENEN Q9NZ42 1/20 0.42
KMT2A Q03164 1/20 0.42
CCR9 P51686 2/20 0.40
ALDH1A1 P00352 1/20 0.39
EDNRA P25101 2/20 0.39
PIK3CD O00329 1/20 0.39
PIK3CB P42338 1/20 0.39
MTOR P42345 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2120124 0.85 TRIM24 (0.48) POLBRAB9ASLC40A1CYP3A4ALDH1A1
SCHEMBL2118088 0.84 RAB9A (0.47) LMNAPOLBRAB9ASLC40A1ALDH1A1
SCHEMBL2119877 0.81 EDNRA (0.40) LMNAPKMPOLBRAB9ACYP3A4
SCHEMBL2117134 0.81 SLC40A1 (0.46) LMNAPKMPOLBSLC40A1CYP3A4
SCHEMBL2119292 0.79 CCR9 (0.48) LMNAPKMPOLBRAB9ACYP3A4
SCHEMBL2119861 0.78 EDNRA (0.39) LMNAPKMPOLBRAB9ACYP3A4
SCHEMBL2119449 0.78 CYP3A4 (0.46) LMNAPKMPOLBRAB9ACYP3A4
SCHEMBL2121588 0.78 CYP3A4 (0.46) LMNAPKMPOLBRAB9ACYP3A4
SCHEMBL2118685 0.78 POLB (0.57) POLBRAB9ACYP3A4CYP2D6PSEN1
SCHEMBL2119257 0.78 POLB (0.48) LMNAPKMPOLBRAB9ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed
EP-2382190-A1 TOLUIDINE SULFONAMIDES AND THEIR USE AS-INHIBITORS European Molecular Biology Laboratory (EMBL) (DE) 2011-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1A, HIF1AN, EGLN3 LMNA 2810/4885PKM 886/4885POLB 1880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.